



November 20, 2014

## BioCryst to Present at Two Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2014 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (Nasdaq:BCRX) today announced that [executives from BioCryst](#) are scheduled to provide a corporate update regarding the Company at the following investor conferences:

- The 26th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 8:30 a.m. Eastern Time
- The Oppenheimer 25th Annual Healthcare Conference in New York on Wednesday, December 10, 2014 at 9:45 a.m. Eastern Time

Links to a live audio webcast and replay of the presentations may be accessed on the BioCryst website events page at <http://investor.shareholder.com/biocryst/events.cfm>.

### About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, including [BCX4161](#) and several second generation compounds; [RAPIVAB](#)<sup>TM</sup> (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, and [BCX4430](#), a broad spectrum viral RNA polymerase inhibitor. For more information, please visit the Company's website at [www.BioCryst.com](http://www.BioCryst.com).

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.

BCRXW

CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910



Source: BioCryst Pharmaceuticals

News Provided by Acquire Media